Enantioselective pharmacokinetic-pharmacodynamic modelling of carvedilol in a NG-nitro-l-arginine methyl ester rat model of secondary hypertension

Journal of Pharmacy and Pharmacology

Volumn 62, Issue 7, 2010, Pages 890-900

  Di Verniero, Carla Andrea ^a   Bertera, Facundo ^a   Buontempo, Fabián ^b   Bernabeu, Ezequiel ^b   Chiappetta, Diego ^a   Mayer, Marcos Alejandro ^a   Bramuglia, Guillermo Federico ^a   Taira, Carlos Alberto ^a   Höcht, Christian ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b Hospital de Pediatria SAMIC Prof Dr Juan P Garrahan   (Argentina)

Author keywords

carvedilol; enantioselective pharmacokinetics; hypertension; PK PD modelling; sympathetic vascular activity

Indexed keywords

CARVEDILOL; N(G) NITROARGININE METHYL ESTER; TAP WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE VARIABILITY; BLOOD SAMPLING; BRADYCARDIA; CHRONOTROPISM; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG POTENCY; ENANTIOSELECTIVITY; HEART RATE VARIABILITY; HYPERTENSION; HYPOTENSION; MALE; NONHUMAN; RAT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARBAZOLES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPERTENSION; MALE; METABOLIC DETOXICATION, DRUG; MODELS, BIOLOGICAL; NG-NITROARGININE METHYL ESTER; PROPANOLAMINES; RANDOM ALLOCATION; RATS; RATS, WISTAR; STEREOISOMERISM; SYMPATHOLYTICS;

EID: 77953988949     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.62.07.0010     Document Type: Article

References (42)

1. Höcht C et al. Pharmacokinetic-pharmacodynamic modeling of antihypertensive drugs: from basic research to clinical practice. Curr Hypertens Rev 2008 4 : 289 302.
2. Bertera FM et al. Increased sensitivity to diltiazem hypotensive effect in an experimental model of high-renin hypertension. J Pharm Pharmacol 2009 61 : 79 87.
3. Höcht C et al. Pharmacokinetic-pharmacodynamic (PK-PD) modeling of cardiovascular effects of metoprolol in spontaneously hypertensive rats: a microdialysis study. Naunyn Schmiedebergs Arch Pharmacol 2006 373 : 310 318.
4. Baek IH et al. Pharmacokinetic/pharmacodynamic modeling of the cardiovascular effects of beta blockers in humans. Arch Pharm Res 2008 31 : 814 821.
5. Höcht C et al. Pharmacokinetic-pharmacodynamic properties of metoprolol in chronic aortic coarctated rats. Naunyn Schmiedebergs Arch Pharmacol 2004 370 : 1 8.
6. Su DF. Treatment of hypertension based on measurement of blood pressure variability: lessons from animal studies. Curr Opin Cardiol 2006 21 : 486 491.
7. Fazan R Jr. et al. Sildenafil acts on the central nervous system increasing sympathetic activity. J Appl Physiol 2008 104 : 1683 1689.
8. Furlan R et al. Sympathetic overactivity in active ulcerative colitis: effects of clonidine. Am J Physiol Regul Integr Comp Physiol 2006 290 : R224 R232.
9. Keating GM, Jarvis B. Carvedilol: a review of its use in chronic heart failure. Drugs 2006 63 : 1697 1741.
10. Bartsch W et al. Pharmacological characteristics of the stereoisomers of carvedilol. Eur J Clin Pharmacol 1990 38 (Suppl. 2 S104 S107.
11. Prakash AK, Kumar A. Effect of chronic treatment of carvedilol on oxidative stress in an intracerebroventricular streptozotocin induced model of dementia in rats. J Pharm Pharmacol 2009 61 : 1665 1672.
12. Ruffolo RR Jr. et al. The pharmacology of carvedilol. Eur J Clin Pharmacol 1990 38 (Suppl. 2 S82 S88.
13. Stahl E et al. Carvedilol stereopharmacokinetics in rats: affinities to blood constituents and tissues. Arch Pharm (Weinheim) 1993 326 : 529 533.
14. Fujimaki M. Stereoselective disposition and tissue distribution of carvedilol enantiomers in rats. Chirality 1992 4 : 148 154.
15. Török J. Participation of nitric oxide in different models of experimental hypertension. Physiol Res 2008 57 : 813 825.
16. Aimone LD. Overview of pharmacokinetics. Curr Protoc Pharmacol 2005 7.1 : 1 26.
17. Pladys P et al. Role of brain and peripheral angiotensin II in hypertension and altered arterial baroreflex programmed during fetal life in rat. Pediatr Res 2004 55 : 1042 1049.
18. Souza HC et al. Heart rate and arterial pressure variability in the experimental renovascular hypertension model in rats. Auton Neurosci 2008 139 : 38 45.
19. Gibaldi M, Perrier D. Pharmacokinetics, 2nd edn.
20. Di Verniero CA et al. In vitro and in vivo pharmacodynamic properties of metoprolol in fructose-fed hypertensive rats. J Cardiovasc Pharmacol 2008 51 : 532 541.
21. van Steeg TJ et al. Pharmacokinetic-pharmacodynamic modelling of S(-)-atenolol in rats: reduction of isoprenaline-induced tachycardia as a continuous pharmacodynamic endpoint. Br J Pharmacol 2007 151 : 356 366.
22. D'Argenio DZ, Schumitzky A. ADAPT II User's Guide: Pharmacokinetic/ Pharmacodynamic Systems Analysis Software.
23. Jusko WJ, Ko HC. Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther 1994 56 : 406 419.
24. Phuong NT et al. Enantioselective pharmacokinetics of carvedilol in human volunteers. Arch Pharm Res 2004 27 : 973 977.
25. Zhou HH, Wood AJ. Stereoselective disposition of carvedilol is determined by CYP2D6. Clin Pharmacol Ther 1995 57 : 518 524.
26. Neugebauer G et al. Stereoselective disposition of carvedilol in man after intravenous and oral administration of the racemic compound. Eur J Clin Pharmacol 1990 38 (Suppl. 2 S108 S111.
27. Ishida K et al. Stereoselective oxidation and glucuronidation of carvedilol in human liver and intestinal microsomes. Biol Pharm Bull 2008 31 : 1297 1300.
28. Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 2008 64 : 1147 1461.
29. Terao N, Shen DD. Alterations in serum protein binding and pharmacokinetics of l-propranolol in the rat elicited by the presence of an indwelling venous catheter. J Pharmacol Exp Ther 1983 227 : 369 375.
30. Frishman WH. Carvedilol. N Engl J Med 1998 339 : 1759 1765.
31. Louis WJ et al. A pharmacokinetic study of carvedilol (BM 14.190) in elderly subjects: preliminary report. J Cardiovasc Pharmacol 1987 10 (Suppl. 11 S89 S93.
32. Stahl E et al. Saturable enantioselective first-pass effect for carvedilol after high oral racemate doses in rats. Arch Pharm (Weinheim) 1993 326 : 123 125.
33. Le Quellec A et al. Microdialysis: an alternative for in vitro and in vivo protein binding studies. Pharm Res 1994 11 : 835 838.
34. Herrera AM et al. Microdialysis sampling for determination of plasma protein binding of drugs. Pharm Res 1990 7 : 1077 1081.
35. Tenero DM et al. Development of a pharmacokinetic/pharmacodynamic model for carvedilol to predict beta1-blockade in patients with congestive heart failure. Am J Cardiol 2006 98 : 27L 31L.
36. Grassi G. Role of the sympathetic nervous system in human hypertension. J Hypertens 1998 16 : 1979 1987.
37. Augustyniak RA et al. L-NAME- and ADMA-induced sympathetic neural activation in conscious rats. Am J Physiol Regul Integr Comp Physiol 2006 290 : R726 R732.
38. Biancardi VC et al. Sympathetic activation in rats with L-NAME-induced hypertension. Braz J Med Biol Res 2007 40 : 401 408.
39. Stauss HM. Identification of blood pressure control mechanisms by power spectral analysis. Clin Exp Pharmacol Physiol 2007 34 : 362 388.
40. Ponchon P, Elghozi JL. Contribution of humoral systems to the short-term variability of blood pressure after severe hemorrhage. Am J Physiol 1997 273 : R58 R69.
41. Perlstein I et al. Power spectral analysis of heart rate variability in rats as a quantitative tool in the PK-PD analysis of the parasympatholytic activity of atropine. Pharm Res 2001 18 : 1220 1225.
42. Watanabe K et al. Contribution of sympathetic nervous system activity during administration of carvedilol in rats with dilated cardiomyopathy. J Cardiovasc Pharmacol 2003 42 (Suppl. 1 S93 S97.